More Related Content Similar to Overview of Medications to Treat Addiction in Primary Care (20) More from Center on Addiction (13) Overview of Medications to Treat Addiction in Primary Care5. Addiction
For information on screening,
diagnosis, treatment planning
& management
Overview of Addiction
Medicine for Primary Care2
(62 Slides)
Overview of Addiction
Medicine for Primary Care:
Supplement3 (30 Pages)
© CASAColumbia 2014
5
6. Stabilization
• Withdrawal in some cases can be lifethreatening
• Medical management for
stabilization/detoxification may be required
• Details for these topics can be found on Pages
88-92 of the CASAColumbia® report Addiction
Medicine: Closing the Gap between Science and
Practice1
© CASAColumbia 2014
6
7. Addiction Treatment
• Treat addiction as a primary disease
• Address tobacco/nicotine, alcohol & other drugs
• Manage co-occurring disorders
dopamine
transporters
© CASAColumbia 2014
7
9. Combined Treatment
• To achieve the best results medications should
be combined with psychosocial therapies
• Research studies illustrate the effectiveness of
various combinations of treatment4-6
• Details for psychosocial therapies can be found
on Pages 102-106 of the CASAColumbia® report
Addiction Medicine: Closing the Gap between
Science and Practice1
© CASAColumbia 2014
9
10. Specialist Referral
Consider for Complex Cases
• Addiction medicine physicians
find a doctor near you
• Addiction psychiatrists
find a doctor near you
Addiction medicine physician: http://www.abam.net/find-a-doctor
Addiction psychiatrist: https://application.abpn.com/verifycert/verifyCert.asp?a=4
© CASAColumbia 2014
10
12. FDA-Approved Meds
Tobacco/Nicotine
• varenicline (Chantix)
• bupropion (Zyban, Wellbutrin)
• nicotine replacement therapy
(e.g., patch, gum, lozenge,
inhaler, nasal spray)
• combinations
• combine with psychosocial therapies
© CASAColumbia 2014
12
13. varenicline
(Chantix)
• 3X higher odds of
smoking cessation7
• Nicotinic acetylcholine
receptor partial
agonist8
• Superior to bupropion
& single-form nicotine
replacement therapy9
© CASAColumbia 2014
13
15. varenicline
(Chantix)
• Black Box Warning: neuropsychiatric events
• Common Side Effects: headache, insomnia,
nausea, abnormal dreams
• FDA Warning: increased risk of CV events in
patients with known CVD
• Meta-analyses show no increased risk of
neuropsychiatric events9 or cardiac events9-10
© CASAColumbia 2014
15
18. bupropion
(Zyban, Wellbutrin)
• Black Box Warning: neuropsychiatric events
• Contraindications: seizure disorder /
predisposition; abrupt cessation of alcohol /
sedatives; risky use / addiction involving alcohol
• Common Side Effects: insomnia, tachycardia,
weight loss, headache, lower seizure threshold
• Meta-analysis shows no increased risk of
neuropsychiatric events9
© CASAColumbia 2014
18
20. nicotine replacement
(Nicoderm, Nicorette, Commit, Nicotrol)
• Contraindications: severe angina, postmyocardial infarction, pregnancy,
hypersensitivity
• Side Effects: minimal except nasal spray (local
irritation, cough, headache, dyspepsia)
• Combination long-acting (e.g., patch) & shortacting (e.g., gum) better than single form13
© CASAColumbia 2014
20
21. nicotine replacement
(Nicoderm, Nicorette, Commit, Nicotrol)
Dosing for 1 cigarette
1mg of nicotine
• Patch (OTC): 7/14/21mg, q12-24hr, 8wk taper
• Gum (OTC): 2/4mg, q1-2hr, 3mo taper
• Lozenge (OTC): 2/4mg, q1-2hr, 3mo taper
• Inhaler (Rx): 6-16 cartridges, q24hr, 3-6mo taper
• Nasal Spray (Rx): 1-2 sprays, q1hr, 3-6mo taper
© CASAColumbia 2014
21
22. nicotine replacement
(Nicoderm, Nicorette, Commit, Nicotrol)
Delivery method characteristics
• Patch (OTC): only long-acting method
• Gum (OTC): “chew & park” technique crucial;
should not be used with acidic food or liquids
• Inhaler (Rx): beneficial for behavioral rituals
• Nasal Spray (Rx): fastest absorption, most side
effects
© CASAColumbia 2014
22
26. acamprosate
(Campral)
• Begin once abstinent for >24hr if possible
• Dose at 666mg TID x 6mo
• Safe even with severe hepatic disease
• Contraindication: severe renal disease
• Common Side Effects: diarrhea, fatigue
© CASAColumbia 2014
26
29. disulfiram
(Antabuse)
• Starting dose: 250-500mg QD x 1-2wk
• Maintenance dose: 125-500mg QD x 6mo
• Clinicians often start & maintain at 250mg QD
• Remains active 14 days after discontinuation
• Contraindications: severe myocardial occlusive
disease, psychosis, hypersensitivity
• Side Effects: hepatitis, psychosis
© CASAColumbia 2014
29
30. naltrexone
(ReVia, Depade, Vivitrol)
• Decreases drinking by
83% over placebo17
• FDA-approved for
alcohol or opioids
• Mu opioid receptor
inhibitor
• Genetic factors affect
efficacy
© CASAColumbia 2014
30
31. naltrexone
(ReVia, Depade, Vivitrol)
• Only begin after abstinence from opioids >7dy
• Starting oral dose
25mg QD (Day 1), 50mg QD (Day 2)
• Maintenance oral dose 50mg QD x 6mo
• Depot dose 380mg IM q4wk: better compliance
• Trial of at least 3mo recommended
© CASAColumbia 2014
31
32. naltrexone
(ReVia, Depade, Vivitrol)
• Black Box Warning: hepatotoxicity
• Contraindications: acute hepatitis, liver failure,
prescribed opioids
• Side Effects: headache, GI distress, syncope,
LFT elevation
• Literature review suggests no increased risk for
causing or worsening hepatic disease18-19
© CASAColumbia 2014
32
35. buprenorphine/naloxone
(Subutex, Suboxone, Zubsolv)
• Reduced use & better treatment retention20
• Partial opioid agonist + opioid antagonist
• Exercise caution in quantities prescribed per visit
due to potential for misuse
• Special training required in order to prescribe
• See details under section “For Physicians” at
buprenorphine.samhsa.gov
© CASAColumbia 2014
35
36. buprenorphine/naloxone
(Subutex, Suboxone, Zubsolv)
• Starting dose
8mg QD (Day 1)
16mg QD (Day 2-3)
• Maintenance dose 12-16mg QD
• Contraindication: hypersensitivity
• Side Effects: respiratory
depression, headache, pain,
insomnia, GI symptoms
© CASAColumbia 2014
36
38. methadone
(Methadose)
• Starting dose 20-40mg QD
• Maintenance dose 80-120mg QD
• Dose may be less depending on baseline opioid
use
• Must follow licensed facility protocol, e.g., EKGs
© CASAColumbia 2014
38
41. FDA-Approved Meds
Other Drugs
• Currently no FDA-approved
medications for addiction
involving other drugs
• Research & development
ongoing for marijuana,
cocaine, others
• Combine with psychosocial
therapies
© CASAColumbia 2014
41
43. For Prescription Drugs
Always consider risks of
addiction if prescribing
• Opioids
• Benzodiazepines
• Stimulants
• Other addictive
prescription drugs
© CASAColumbia 2014
43
44. For Adolescent Patients
• Only buprenorphine/naloxone
is FDA-approved for 16 years
& older
• All other medications are
FDA-approved for 18 years &
older
• Adolescent treatment should
focus more on psychosocial
therapies
© CASAColumbia 2014
44
45. For Elderly Patients
• Monitor for drug-drug interactions
• For renal insufficiency adjust dosing of
varenicline, bupropion, acamprosate,
methadone
• For hepatic insufficiency adjust dosing of
bupropion, buprenorphine/naloxone,
methadone, naltrexone (contraindication if
severe)
© CASAColumbia 2014
45
46. References
1. CASAColumbia. Addiction medicine: closing the gap between science and practice. 2012 Jun.
http://www.casacolumbia.org/addiction-research/reports/addiction-medicine
2. CASAColumbia. Addiction medicine: primary care clinical guide. 2013 Aug. http://www.casacolumbia.org/health-careproviders/guide
3. CASAColumbia. Addiction medicine: primary care clinical guide supplement. 2013 Aug. http://www.casacolumbia.org/health-careproviders/guide-supplement
4. Amato L, et al. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane
Database Syst Rev. 2011 Sep 7;(9):CD005031.
5. Anton RF, et al. Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence.
J Clin Psychopharmacol. 2005 Aug;25(4):349-57.
6. Feeney GF, et al. Cognitive behavioural therapy combined with the relapse-prevention medication acamprosate: are short-term
treatment outcomes for alcohol dependence improved? Aust N Z J Psychiatry. 2002 Oct;36(5):622-8.
7. Fiore MC, et al. Clinical practice guideline. Treating tobacco use and dependence: 2008 update. U.S. Department of Health and
Human Services, 2008 May.
8. U.S. Food and Drug Administration. Highlights of prescribing information for Chantix (varenicline). 2013 Feb.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021928s030lbl.pdf
9. Cahill K, et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database
Syst Rev. 2013 May 31;5:CD009329.
10. Prochaska JJ, et al. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic
review and meta-analysis. BMJ 2012; 344:e2856.
© CASAColumbia 2014
46
47. References
11. Hughes JR, et al. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD000031.
12. U.S. Food and Drug Administration. Prescribing information: Zyban (bupropion hydrochloride). 2012 Jan.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020711s036lbl.pdf
13. Stead LF, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012 Nov 14;11:CD000146.
14. Rösner S, et al. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010 Sep 8;(9):CD004332.
15. U.S. Food and Drug Administration. Highlights of prescribing information for Campral (acamprosate calcium). 2012 Jan.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021431s015lbl.pdf
16. Laaksonen E, et al. A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the
treatment of alcohol dependence. Alcohol Alcohol. 2008 Jan-Feb;43(1):53-61.
17. Rösner S, et al. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD001867.
18. Brewer C, et al. Naltrexone: report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literature. Addict Biol. 2004
Mar;9(1):81-7.
19. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. Naltrexone: LiverTox Clinical and
Research Information on Drug-Induced Liver Injury. http://livertox.nih.gov/Naltrexone.htm
20. Mattick RP, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane
Database Syst Rev. 2008 Apr 16;(2):CD002207.
21. Mattick RP, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane
Database Syst Rev. 2009 Jul 8;(3):CD002209.
© CASAColumbia 2014
47
48. Acknowledgements
• Margot Cohen contributed much of the research
and writing for these materials.
• The following subject-matter experts served as
external reviewers for these materials: Kevin
Kunz, M.D., M.P.H., Frances Levin, M.D.,
Charles O’Brien, M.D., Ph.D.
• Funding was provided by The Joseph A.
Califano, Jr. Institute for Applied Policy.
© CASAColumbia 2014
48